ERBB2 and breast carcinoma: In the same Erbb2-driven mammary carcinoma model, expression of activated Akt1 or Akt2, in which the Thr308 and Ser473 residues were replaced with phosphomimetic Asp residues (Akt1 T308D S473D and Akt2 T308D S473D), resulted in increased pulmonary metastases and tumor invasiveness, particularly in the case of activated Akt2 [260–262].